What is Nicotinamide Riboside (NR)?

Nicotinamide riboside is a vitamin B3-related NAD+ precursor distinct from NMN and direct NAD+. [1][2][3]

The oral and injectable routes use separate evidence: controlled oral trials support daily capsules, while the vial schedule remains investigational and product-specific. [1][2][3]

What Nicotinamide Riboside (NR) is investigated for

Nicotinamide Riboside (NR) evidence is grouped by practical use case and oral and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Oral NAD+ biomarker support

Oral

74% Moderate

Oral NAD+ biomarker restoration is the most reproducible NR finding; it should not be treated as proof of symptom, disease, or longevity benefit. [1][12][13]

Human evidence

Randomized studies show reproducible, dose-responsive increases in whole-blood NAD+ and related metabolites, with evidence extending to cerebral and skeletal-muscle NAD biology. [1][2][3][17][10]

Animal / mechanistic evidence

Animal and biochemical work established the precursor rationale, but the confidence score here is driven by controlled human biomarker studies. [26][24][25]

Walking performance in peripheral artery disease

Oral

60% Emerging

The walking signal is promising but condition-specific and needs larger independent confirmation before routine clinical claims. [7][13]

Human evidence

The NICE randomized clinical trial in peripheral artery disease reported a modest improvement in six-minute walk distance after six months, with a stronger exploratory signal in a combination arm. [7]

Animal / mechanistic evidence

Preclinical vascular and mitochondrial rationale exists, but the clinical confidence rests on one condition-specific trial. [26][12]

Neurocognitive support

Oral

52% Emerging

NR is an active research strategy for neurologic conditions, not an established cognitive enhancer or neurodegenerative treatment. [5][6][23]

Human evidence

Trials in mild cognitive impairment, subjective cognitive decline, and Parkinson's disease show blood or neurodegeneration-biomarker changes, but cognitive and disease-modifying outcomes remain inconsistent or unproven. [20][5][6][23]

Animal / mechanistic evidence

Extensive neuroprotective rationale exists in model systems, but it does not resolve the mixed human clinical findings. [26][12]

Cardiometabolic health

Oral

44% Preliminary

Cardiometabolic use remains exploratory and should not be represented as a proven glucose, lipid, blood-pressure, or weight-loss intervention. [18][15][14]

Human evidence

Studies report some exploratory vascular signals, but multiple controlled trials found no meaningful improvement in insulin sensitivity, lipids, mitochondrial respiration, or broad body composition. [2][18][15][14][22]

Animal / mechanistic evidence

Preclinical metabolic benefits are stronger and more consistent than the human outcome evidence. [26][12]

Healthy aging and longevity

Oral

16% Insufficient

NR should be described as a studied NAD+ precursor, not a proven anti-aging or lifespan-extending treatment. [12][13]

Human evidence

Human trials demonstrate NAD+ biomarker engagement but not lifespan extension or broad prevention of age-related disease. [12][13]

Animal / mechanistic evidence

Aging-pathway and animal evidence motivates human study but cannot establish a human longevity effect. [26][12]

Evidence snapshot

Overall confidence

Moderate

66%

NR has controlled oral human data and early injectable research. [1][2][3][28][31]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

70%

Human evidence

Moderate

Human data are strongest for oral NR; injection evidence is early and protocol-focused. [1][2][3][28]

28%

Animal / preclinical

Limited

The approved defaults rely on route-matched human or protocol sources rather than animal dose extrapolation. [1][2][3]

72%

Mechanism support

Moderate

NR enters NAD+ biosynthesis through nicotinamide riboside kinase pathways. [1][2][3]

Forms & administration

NR exposes one oral form and one NR-chloride vial form. The sourced commercial kit remains searchable and in provenance, but it is not shown as the canonical medication name. [1][2][3][28][31]

OralInjectable

Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

Typical Range

Oral protocols commonly use 300 mg per day. Injectable research protocols use 50 mg per dose. [1][2][3][28][31]

Frequency

Oral NR is taken once daily. Injection schedules use daily doses for 3 days, then 3 doses weekly. [1][28]

Timing Considerations

Morning is the usual timing. [1][2][3][28]

Cycle Length

Oral protocols may run 8 weeks. Injectable research schedules may continue to day 100. [1][28]

What to expect

First 1–2 weeks

Blood NAD+ and related metabolites can rise early, but a biomarker response does not predict a noticeable clinical effect. [19][1]

Weeks 4–8

Most short trials reassess NAD+ biomarkers, tolerability, and condition-specific exploratory outcomes in this window; many metabolic and cognitive outcomes remain unchanged. [1][5][6]

Months 3–6

Longer condition-specific trials may be needed for functional outcomes; the PAD walking signal was measured over six months and should not be generalized to healthy users. [7]

After stopping

NAD-related biomarker gains are not expected to represent a permanent change, but exact washout timing and symptom durability are not consistently mapped across trials. [2][12]

Safety profile

Oral NR has controlled human tolerability data across several short trials, including a high-dose Parkinson's safety study, without a consistent excess pattern of serious adverse events. Long-term and injectable safety remain less certain. [1][2][4][32]

Cautions

Oral trial tolerability [1][4][5]
Injectable sterility and preparation [28][31][32]

What we don't know

Multi-year use, pregnancy, pediatric use, and injectable safety remain incompletely characterized. [12][13][28]

Who Nicotinamide Riboside (NR) is not for

Route-specific avoid and medical-review notes:

Pregnancy or breastfeeding without clinician review
Pregnancy and breastfeeding safety data are insufficient for the reviewed oral and investigational injectable use. [12][13]

Regulatory status

United States

Nicotinamide Riboside (NR) is not FDA-approved as a drug for the reviewed routes. Compounded, supplement, and research-market availability are separate from FDA approval. [32][29]

Route	FDA drug approval	503A compounding
Oral	Not Approved Nicotinamide Riboside (NR) is not FDA-approved as a oral drug for the reviewed use. Compounded, supplement, or research availability is separate from FDA approval. [32]	Not Listed Nicotinamide Riboside (NR) does not have FDA-approved oral dosing for the reviewed use; any compounded preparation remains product- and prescriber-specific. [32]
Injectable	Not Approved Nicotinamide Riboside (NR) is not FDA-approved as a injectable drug for the reviewed use. Compounded, supplement, or research availability is separate from FDA approval. [32]	Not Listed Nicotinamide Riboside (NR) does not have FDA-approved injectable dosing for the reviewed use; any compounded preparation remains product- and prescriber-specific. [32]

Oral

FDA drug approval

Not Approved

Nicotinamide Riboside (NR) is not FDA-approved as a oral drug for the reviewed use. Compounded, supplement, or research availability is separate from FDA approval. [32]

503A compounding

Not Listed

Nicotinamide Riboside (NR) does not have FDA-approved oral dosing for the reviewed use; any compounded preparation remains product- and prescriber-specific. [32]

Injectable

FDA drug approval

Not Approved

Nicotinamide Riboside (NR) is not FDA-approved as a injectable drug for the reviewed use. Compounded, supplement, or research availability is separate from FDA approval. [32]

503A compounding

Not Listed

Nicotinamide Riboside (NR) does not have FDA-approved injectable dosing for the reviewed use; any compounded preparation remains product- and prescriber-specific. [32]

International

Nicotinamide riboside chloride is authorized for specified uses and conditions in the European Union novel-food framework; authorization is ingredient- and condition-specific, not drug approval. [30]

Sports & competition

Tested athletes should obtain sport-specific review for non-approved NAD-pathway products. [34]

How it works

Oral NR is absorbed and metabolized through pathways that can raise circulating NAD-related metabolites. Controlled studies demonstrate biomarker changes across several daily doses. [1][2][3]

Injectable NR chloride bypasses oral delivery but remains an investigational route. Its preparation and cadence come from a specific human safety protocol rather than from direct NAD+ practice. [1][2][3][28]

Research gaps & open questions

What the current literature has not yet settled about Nicotinamide Riboside (NR):

Injectable NR needs larger placebo-controlled studies that measure safety, blood levels, tissue exposure, and clinical outcomes. [1][2][3]

Long-term clinical outcomes need independent testing that goes beyond changes in NAD-related blood biomarkers. [1][2][3]

The peripheral-artery-disease walking signal needs larger replication and clarity on which patients, co-interventions, and outcomes are most responsive. [7][13]

Neurologic trials need clearly chosen clinical outcomes and enough duration to distinguish biomarker movement from cognitive or disease-modifying benefit. [5][6][23]

Research should define long-term safety and clinically meaningful outcomes in older adults, chronic-disease populations, and people taking multiple medications. [12][13]

Common questions

Is NR direct NAD+?

No. NR is a precursor that can be converted through NAD+ biosynthetic pathways. [1][2][3]

Why does the vial use NR chloride as the medication name?

The canonical molecule is nicotinamide riboside, so the sourced commercial kit remains searchable and in provenance rather than replacing the medication identity. [28][31]

Does NR have proven anti-aging or longevity benefits?

No human trial has shown lifespan extension. NR reliably raises NAD-related biomarkers, but clinical outcome results are mixed and condition-specific. [12][13]

Does NR improve memory or treat neurodegenerative disease?

Not established. Trials report some NAD-related or disease-biomarker changes, but cognitive and disease-modifying benefit has not been consistently demonstrated. [5][6][23]

Does oral NR evidence validate injectable NR?

No. Oral trials cannot establish the pharmacokinetics, sterility, safety, or clinical outcomes of an injectable NR-chloride product; the injectable route remains investigational. [1][28][32]

Myths & misconceptions

Myth

An NR vial is a generic NAD+ vial.

Reality

NR chloride and direct NAD+ are different molecules with separate dose and preparation records. [1][2][3][28]

Myth

A higher blood NAD+ result proves that NR is improving health.

Reality

Blood NAD+ is a target-engagement biomarker. Multiple trials raised NAD-related measures without improving the main metabolic, muscle, or cognitive outcomes studied. [18][15][5]

Myth

Food or supplement availability means NR is an FDA-approved drug.

Reality

No. Food/supplement status, a GRAS notice response, and FDA drug approval are different regulatory pathways. [29][32]

History & discovery

Nicotinamide riboside is a vitamin B3 form and NAD+ precursor. Human development progressed from oral bioavailability and pharmacokinetic studies to randomized trials across healthy aging, metabolic, neurologic, vascular, and mobility contexts. Across that history, NAD+ biomarker engagement has been more reproducible than clinical benefit. [27][19][12][13]

NR was contextualized alongside nicotinic acid and nicotinamide as a human NAD+ precursor vitamin. [27]

Human studies established oral bioavailability, blood NAD+ increases, and short-term tolerability across controlled exposure ranges. [25][2][1]

Trials expanded into neurologic, vascular, pulmonary, muscle, and mobility outcomes, with mixed clinical results despite biomarker engagement. [20][7][21][23]

Published research 30 studies

[1]

Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults

Scientific Reports, 2019. human clinical.

[2]

Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults

Nature Communications, 2018. human clinical.

[3]

Acute nicotinamide riboside supplementation increases human cerebral NAD+ levels in vivo

Aging Cell, 2024. human clinical.

[4]

NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease

Nature Communications, 2023. human clinical.

[5]

A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment

GeroScience, 2024. human clinical.

[6]

Cognitive and Alzheimer's disease biomarker effects of oral nicotinamide riboside supplementation in older adults with subjective cognitive decline and mild cognitive impairment

Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2025. human clinical.

[7]

Nicotinamide riboside for peripheral artery disease: the NICE randomized clinical trial

Nature Communications, 2024. human clinical.

[8]

Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin

Aging Cell, 2023. human clinical.

[9]

Nicotinamide Riboside Supplementation Benefits in Patients With Werner Syndrome: A Double-Blind Randomized Crossover Placebo-Controlled Trial

Aging Cell, 2025. human clinical.

[10]

The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans

Nature Metabolism, 2026. human clinical.

[11]

The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis

Journal of Cachexia, Sarcopenia and Muscle, 2025. review.

[12]

What is really known about the effects of nicotinamide riboside supplementation in humans

Science Advances, 2023. review.

[13]

NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence

Ageing Research Reviews, 2026. review.

[14]

Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans

American Journal of Clinical Nutrition, 2020. human clinical.

[15]

Nicotinamide riboside does not alter mitochondrial respiration, content or morphology in skeletal muscle from obese and insulin-resistant men

The Journal of Physiology, 2020. human clinical.

[16]

Effects of Nicotinamide Riboside on Endocrine Pancreatic Function and Incretin Hormones in Nondiabetic Men With Obesity

Journal of Clinical Endocrinology & Metabolism, 2019. human clinical.

[17]

Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures

Cell Reports, 2019. human clinical.

[18]

A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects

American Journal of Clinical Nutrition, 2018. human clinical.

[19]

An open-label, non-randomized study of the pharmacokinetics of nicotinamide riboside and its effects on blood NAD+ levels in healthy volunteers

PLOS ONE, 2017. human clinical.

[20]

The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease

Cell Metabolism, 2022. human clinical.

[21]

Effect of nicotinamide riboside on airway inflammation in COPD: a randomized, placebo-controlled trial

Nature Aging, 2024. human clinical.

[22]

Nicotinamide riboside combined with exercise to treat hypertension in middle-aged and older adults: a pilot randomized clinical trial

GeroScience, 2025. human clinical.

[23]

A phase-II randomized controlled pilot study of nicotinamide riboside supplementation in older adults with amnestic mild cognitive impairment

Alzheimer's & Dementia, 2026. human clinical.

[24]

Safety assessment of nicotinamide riboside, a form of vitamin B3

Human & Experimental Toxicology, 2016. animal.

[25]

Nicotinamide riboside is uniquely and orally bioavailable in mice and humans

Nature Communications, 2016. human clinical.

[26]

Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 with effects on energy metabolism and neuroprotection

Current Opinion in Clinical Nutrition and Metabolic Care, 2013. review.

[27]

Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition

Annual Review of Nutrition, 2008. review.

[28]

Randomized, Open-label, Safety Study of Subcutaneous and Intramuscular Injections of Niagen Plus

ClinicalTrials.gov, 2025. clinical trial registry.

[29]

Agency Response Letter GRAS Notice No. GRN 000635

U.S. Food and Drug Administration, 2016. regulatory.

[30]

Union list of novel foods

European Commission. regulatory.